Head-to-head evidence
albuterol sulfate (Amphastar) vs Salbutamol HFA-152a
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol sulfate (Amphastar)
Developed by Amphastar Pharmaceuticals, Inc.
NCT01581177 · Phase 2 · completed
The study randomized 23 participants and used triple blinding with placebo and active albuterol comparators, but its small sample and unreported results limit the strength of the evidence. The primary outcome was change in FEV1 AUC, a physiological surrogate measure, and the registry does not state whether this comparison was successful.
Next expected readout: April 2028 · NCT07426458 (registry estimate)
Salbutamol HFA-152a
Developed by GlaxoSmithKline
NCT06261957 · Phase 3 · completed
The trial randomized 477 participants and used quadruple blinding with an active salbutamol comparator. Its primary clinical safety endpoint was the number of participants with adverse events, but results are not posted, so whether the primary comparison was favorable cannot be determined.
Next expected readout: February 2027 · NCT06433921 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol sulfate (Amphastar)'s landscape · Salbutamol HFA-152a's landscape